Ono Pharma Begins Drug Discovery Collaboration with Epsilon

Ono Pharma inks drug discovery collaboration with Epsilon Molecular Engineering aiming at the generation of novel VHH antibody drugs

Overview

Ono Pharmaceutical Co., Ltd., is one of the largest pharmaceutical companies in Japan, announced that it has entered into a drug discovery collaboration agreement with Epsilon Molecular Engineering, INC, (EME) to generate novel VHH antibodies, aiming at the creation of innovative VHH antibody drugs.

Terms of Agreeent

• Under the terms of this agreement, EME will obtain novel humanized VHH antibodies against multiple targets selected by Ono, by leveraging EME’s proprietary humanized VHH screening platform, “The Month”. 

• Ono will conduct various tests to evaluate the activities (in vitro and in vivo assay) of humanized VHH antibodies obtained by EME to discover and develop antibody drug candidates.

• Ono will hold option rights to exclusively develop and commercialize the antibody drug candidates generated through the collaboration worldwide. 

• Ono will pay to EME an upfront payment, and milestone payments based on the progress of research and clinical development.

Impact of VHH Antibody Artificial Library

“The Month” is a high throughput antibody screening platform based on cDNA display technology. By combining that with EME’s proprietary humanized VHH antibody artificial library, PharmaLogical Library, EME can acquire a large number of VHH antibodies in about one month against tough targets that are difficult to obtain with conventional methods. This library has a vast size ranging from 10 trillion to 100 trillion and is specifically designed to reflect the structural features of VHH antibodies, demonstrating antigen recognition distinct from conventional antibodies.

About Epsilon

Epsilon Molecular Engineering, Inc. (EME) is a startup company that has been pioneering the development of innovative biomolecules based on evolutionary molecular engineering since 2016. Leveraging proprietary screening technologies and molecular design methods, EME engages in collaborative research activities primarily in the medical field, focusing on the development of next-generation antibody therapeutics, diagnostic agents, and regenerative medicine reagents.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!